中文版 | English
Title

Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China

Author
Corresponding AuthorLiu, Jiaye
Publication Years
2022-10-01
DOI
Source Title
ISSN
1525-4135
EISSN
1077-9450
Volume91
Abstract
Background: We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC + EFV) and those who received coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF). Methods: We retrospectively reviewed the medical records of 2343 antiretroviral-naive people living with HIV who initiated TDF + 3TC + EFV or E/C/F/TAF. A propensity score matching method was used to compare longitudinal changes of blood lipids between the 2 groups. Results: By using 1:3 matching ratio, we included 253 and 91 matched patients in TDF + 3TC + EFV group and E/C/F/TAF group, respectively. The levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol were higher in E/C/F/TAF group than those in TDF + 3TC + EFV group at 3, 6, 9, and 12 months (Wilcoxon test, all Ps < 0.05), except for high-density lipoprotein cholesterol at 9 and 12 months. The cumulative rates of hypercholesterolemia, hypertriglyceridemia, and high LDL-C in PLWH with normal lipid levels in E/C/F/TAF group were higher than those in TDF + 3TC + EFV group (hypercholesterolemia, 59.7% vs 21.5%, P < 0.001; hypertriglyceridemia, 69.5% vs 46.3%, P < 00.001; and high LDL-C, 41.5% vs 14.2%, P < 0.001). Multivariate analysis showed treatment with E/C/F/TAF was associated with a significantly higher risk of hypercholesterolemia [adjusted hazard ratio (HR), 4.12; 95% confidence interval (CI): 2.65 to 6.41], hypertriglyceridemia (adjusted HR, 1.69; 95% CI: 1.18 to 2.43), and high LDL-C (adjusted HR, 4.60; 95% CI: 2.66 to 7.97). Conclusions: We concluded that treatment with E/C/F/TAF resulted in higher risks of dyslipidemia compared with TDF + 3TC + EFV.
Keywords
URL[Source Record]
Indexed By
Language
English
SUSTech Authorship
First
Funding Project
Sanming Project of Medicine in Shenzhen[SZSM201512029] ; Guangdong Basic and Applied Basic Research Foundation[2019A1515011197] ; Shenzhen Science and Technology Program[JCYJ20190809115617365] ; Science and Technology Innovation Committee of Shenzhen Municipality[JCYJ20170412151650600]
WOS Research Area
Immunology ; Infectious Diseases
WOS Subject
Immunology ; Infectious Diseases
WOS Accession No
WOS:000852773800002
Publisher
ESI Research Field
IMMUNOLOGY
Data Source
Web of Science
Citation statistics
Cited Times [WOS]:0
Document TypeJournal Article
Identifierhttp://kc.sustech.edu.cn/handle/2SGJ60CL/401501
DepartmentThe Third People's Hospital of Shenzhen
Affiliation
1.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Guangdong, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen, Guangdong, Peoples R China
3.Shenzhen Univ, Hlth Sci Ctr, Sch Publ Hlth, Shenzhen, Guangdong, Peoples R China
First Author AffilicationThe Third People's Hospital of Shenzhen
First Author's First AffilicationThe Third People's Hospital of Shenzhen
Recommended Citation
GB/T 7714
Sun, Liqin,He, Yun,Xu, Liumei,et al. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES,2022,91.
APA
Sun, Liqin.,He, Yun.,Xu, Liumei.,Zhao, Fang.,Zhou, Yang.,...&Liu, Jiaye.(2022).Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES,91.
MLA
Sun, Liqin,et al."Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China".JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 91(2022).
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Export to Excel
Export to Csv
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[Sun, Liqin]'s Articles
[He, Yun]'s Articles
[Xu, Liumei]'s Articles
Baidu Scholar
Similar articles in Baidu Scholar
[Sun, Liqin]'s Articles
[He, Yun]'s Articles
[Xu, Liumei]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Sun, Liqin]'s Articles
[He, Yun]'s Articles
[Xu, Liumei]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.